What is the Transmucosal Immediate-Release Fentanyl (TIRF) REMS?
The Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Program is an FDA-required program designed to ensure informed risk-benefit decisions before initiating treatment, and while patients are treated to ensure appropriate use of TIRF medicines. The purpose of the REMS is to mitigate the misuse, abuse, addiction, overdose, and serious complications due to medication errors with the use of TIRF medicines.
You must enroll in the TIRF REMS to prescribe, dispense, or distribute TIRF medicines.
Important Program Update
The TIRF REMS Call Center is experiencing high call volumes. Priority for handling calls will be provided to stakeholders actively involved in filling a prescription for a patient.
To receive treatment, a patient must be enrolled in the TIRF REMS by a certified doctor.